Want to see FR:ALIMP full AI Analyst Report?
Top Page
Implanet SA
(ALIMP)
Select Model
Select Model
Rating:42Neutral
Price Target:
€0.15
▼(-43.85% Downside)
Action:Reiterated
Date:08/06/26
The score is held down primarily by weak financial performance quality: despite strong revenue growth and improving gross margin, the company remains loss-making with negative operating/free cash flow and a highly leveraged, thin-equity balance sheet. Technicals also show a soft trend (below major moving averages, negative MACD), while valuation is not supportive due to negative earnings and no dividend yield data.
Positive Factors
Strong Revenue Rebound
The sharp revenue rebound indicates improving commercial traction and a stronger sales base in the company’s orthopedic and spinal device markets. If maintained, this top-line expansion can improve operating leverage and provide greater scale for future investment in products and distribution.
Negative Factors
Persistent Operating Losses
Persistent operating and net losses show that revenue growth and gross-margin gains have not yet translated into a sustainable earnings model. Continued losses can consume capital, limit internal funding for expansion, and make the business more vulnerable if growth or margins weaken.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Rebound
The sharp revenue rebound indicates improving commercial traction and a stronger sales base in the company’s orthopedic and spinal device markets. If maintained, this top-line expansion can improve operating leverage and provide greater scale for future investment in products and distribution.
Read all positive factors
Implanet SA (ALIMP) vs. iShares MSCI France ETF (EWQ)
Market Cap
€21.86M
Dividend YieldN/A
Average Volume (3M)49.62K
Price to Earnings (P/E)―
Beta (1Y)0.06
Revenue Growth24.35%
EPS Growth15.00%
CountryFR
Employees46
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding143,818,970
10 Day Avg. Volume54,143
30 Day Avg. Volume49,623
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)70.59
Price to Sales (P/S)2.29
P/FCF Ratio-13.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Implanet SA Business Overview & Revenue Model
Company Description
Implanet S.A., together with its associated companies, is dedicated to the research, development, manufacturing, and commercialization of spinal and orthopedic medical implants. The firm's product portfolio addresses both spinal and knee needs. It...
How the Company Makes Money
Implanet generates revenue primarily from selling orthopedic and spine implant products and the associated surgical instruments/ancillaries required to perform procedures using its systems. Revenue is typically recognized through product sales to ...
Implanet SA Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
18
Very Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 13.80M | 12.47M | 9.41M | 7.45M | 8.03M | 6.14M |
| Gross Profit | 8.08M | 5.93M | 4.10M | 3.13M | 3.91M | 2.74M |
| EBITDA | -2.75M | -3.73M | -3.82M | -5.08M | -2.46M | -3.26M |
| Net Income | -4.42M | -4.38M | -4.37M | -6.68M | -3.54M | -4.61M |
Balance Sheet | ||||||
| Total Assets | 17.74M | 18.45M | 14.89M | 10.64M | 14.47M | 16.70M |
| Cash, Cash Equivalents and Short-Term Investments | 1.01M | 3.01M | 1.60M | 248.00K | 531.00K | 1.87M |
| Total Debt | 5.46M | 5.92M | 6.50M | 6.15M | 6.80M | 9.61M |
| Total Liabilities | 19.46M | 18.04M | 14.16M | 10.81M | 10.93M | 13.90M |
| Stockholders Equity | -1.72M | 404.00K | 727.00K | -174.00K | 3.54M | 2.80M |
Cash Flow | ||||||
| Free Cash Flow | -2.29M | -2.15M | -2.81M | -2.17M | -3.04M | -3.91M |
| Operating Cash Flow | -733.00K | -589.00K | -2.32M | -1.45M | -2.47M | -3.52M |
| Investing Cash Flow | -1.62M | -1.56M | -844.00K | -768.00K | -570.00K | 1.57M |
| Financing Cash Flow | 2.96M | 3.64M | 4.37M | 1.95M | 1.60M | 2.73M |
Implanet SA Technical Analysis
Negative
0.26
Price Trends
0.17
Negative
0.18
Negative
0.20
Negative
Market Momentum
>-0.01
Positive
39.65
Neutral
23.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALIMP, the sentiment is Negative. The current price of 0.26 is above the 20-day moving average (MA) of 0.17, above the 50-day MA of 0.17, and above the 200-day MA of 0.20, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 39.65 is Neutral, neither overbought nor oversold. The STOCH value of 23.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALIMP.
Implanet SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | €359.81M | -8.68 | -120.57% | ― | -100.00% | -72.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | €48.84M | -6.36 | 453.10% | ― | -16.98% | 20.31% | |
45 Neutral | €24.25M | 5.91 | -58.93% | ― | 7.43% | ― | |
43 Neutral | €158.30M | -2.81 | 90.10% | ― | 1.79% | 15.89% | |
42 Neutral | €21.86M | -5.50 | 671.47% | ― | 24.35% | 15.00% |
* Healthcare Sector Average
FR:ALIMP
Implanet SA
0.16
-0.23
-59.85%
FR:ALMKT
MAUNA KEA TECHNOLOGIES
0.12
0.03
34.83%
FR:ALTHE
Theraclion SA
0.66
-0.02
-3.24%
FR:ALDMS
Diagnostic Medical Systems
0.90
-0.50
-35.80%
FR:ALMDT
Median Technologies
3.24
<0.01
0.15%
FR:CVX
Affluent Medical SA
5.64
4.24
302.86%
Implanet SA Corporate Events
Implanet lifts H1 revenue 23% as Jazz Spinal System drives margin gains
Sep 15, 2026
Implanet reported first-half 2026 revenue of €7.1 million, up 23% year-on-year, with growth driven by its spine implants business and the strong performance of the new Jazz Spinal System hybrid posterior fixation solution. Sales of the SMTP ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.